Karen Torrejon, PhD
Founder & CSO
Dr. Torrejon founded Glauconix as a PhD candidate at SUNY Polytechnic Institute's College of Nanoscale Science and Engineering. As a PhD candidate Dr. Torrejon received numerous awards and accolades for research accomplishments. Dr. Torrejon is a National Science Foundation Fellow, and an MIT Technology Review Innovator Under 35. Dr. Torrejon has published peer reviewed articles in a number of high-impact journals including Biotechnology and Bioengineering, and Nature.
Feryan Ahmed, PhD
VP, Operations & Business Develpment
Dr. Ahmed leverages 15+ years of pharma industry experience to help manage lab operations and business development. Dr. Ahmed is a chemist and nanoscale scientist with experience in medicinal chemistry, synthetic chemistry, drug discovery,lithography, metrology and nanoparticle chemistry. Prior co-founding Glauconix, Dr. Ahmed worked at Albany Molecular Research, Inc. Dr. Ahmed is a graduate of the University of Minnesota and SUNY Polytechnic College of Nanoscale Science and Engineering.
MaryJane Rafii, PhD/MBA
Dr. Rafii is currently serving as the Interim CEO of Glauconix Biosciences. Previously she was the Senior Director, Corporate Development and Strategy, at Ora Inc. Ora is the world's leading independent, full-service ophthalmic drug and device development firm with offices in the United States and Japan. Over the past 30 years, Ora has played a key role in over 40 regulatory approvals in the US. Dr Rafii was also the Co-founder and a Board Member of JADE Therapeutics, an ophthalmology focused company based in Salt Lake City, UT. Jade Therapeutics' idea was based on unmet medical need in the ocular disease area. Dr. Rafii was instrumental in the acquisition of Jade Therapeutics by Eyegate Pharmaceuticals in March 2016.
Dr. Rafii previously served as Early Asset Lead at Pfizer Worldwide Research and Development in New York for all Ophthalmology, Neuroscience and Pain assets and also as a Medical Lead for the Specialty Care Business Unit (SCBU) - Ophthalmology and Neuroscience. Prior to Pfizer, she served as Chief Medical Officer for Fovea Pharmaceuticals in Paris, which was successfully acquired by Sanofi Aventis in 2009.
Dr Rafii has held executive roles at Bioenvision Inc., an oncology focused publicly traded company acquired by Genzyme, as well as the Ludwig Institute for Cancer Research (LICR) and LifeCycle Pharma all based in New York City. Dr Rafii has a PhD from Cardiff University in Ophthalmology and a Master of Science in Biochemistry, Stanford University, Palo Alto, CA, and obtained her Bachelor of Science in Molecular Biology, University of Southern California, Los Angeles, CA.
James Guzewich, CPA
Mr. Guzewich manages accounting, finance and associated management duties.
Prior to Glauconix, Mr. Guzewich ten years of progressive advancement as CFO, COO and CEO of the VersaTrans Solutions division of Tyler Technologies, a $300 million software company. He previously served as CFO of an insurance services corporation, a professional medical liability insurance company, Key Corp Leasing Ltd., Contec International, as well as a couple of start-ups.
Mr. Guzewich worked for Key Corp. in evaluating and conducting due diligence of bankers and other financial entity targets. He is a CPA, having worked at Ernst & Whinney for twelve years.
Mr. Guzewich has served as an adjunct professor at SUNY Albany and Rensselaer Polytechnic Institute, and graduated with a B.A. from SUNY Oneonta and a M.S. from SUNY Binghamton